Chembio Announces Oral Presentation and Multiple Poster Presentations at 2012 HIV Diagnostics Conference

Chembio Announces Oral Presentation and Multiple Poster Presentations at 2012
HIV Diagnostics Conference

Company Highlights the Clinical Utility of Its Dual Path Platform Rapid,
Point-of-Care Tests in HIV and Related Infectious Diseases including Syphilis
and Hepatitis-C

MEDFORD, N.Y., Dec. 13, 2012 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.
(Nasdaq:CEMI),a leader in point-of-care diagnostic tests for infectious
diseases, announces that an oral presentation and multiple poster
presentations underscoring the clinical utility of the Company's Dual Path
Platform^® rapid, point-of-care (POC) diagnostic tests are being presented at
the 2012 HIV Diagnostics Conference being held December 12-14 at the Sheraton
Atlanta Hotel.

An oral presentation entitled "Performance Evaluation of the DPP® HIV-SYPHILIS
Assay: a novel, point-of-care rapid HIV 1/2, and Syphilis Treponema pallidum
Antibody Combination Test" was delivered by Javan Esfandiari, Senior Vice
President of Research and Development for Chembio.The presentation was made
in conjunction with the "Testing for HIV/Hepatitis or HIV/Syphilis
Co-infections" workshop moderated by Kelly Wroblewski, Association of Public
Health Laboratories, which took place at 4:00 p.m. local time on December
12^th.

In his presentation on Wednesday, Mr. Esfandiari showcased the Company's DPP^®
HIV-SYPHILIS, a single-use immunochromatographic, rapid screening test for the
detection of antibodies to HIV 1/2 and Syphilis Treponema pallidum in
fingerstick whole blood, venous whole blood, serum or plasma.Data have shown
the test to have accurate results with documented sensitivity and specificity
for both HIV 1/2 and Syphilis antibodies on one device.

Mr. Esfandiari noted, "In the U.S., approximately 16% of patients, as well as
28% of men, who are infected with syphilis are also co-infected with HIV.As a
result, there is growing interest in an accurate, rapid POC test that can
diagnose both HIV and syphilis antibodies.Moreover, syphilis facilitates HIV
transmission, making an early and accurate syphilis diagnosis key to
preventing continued transmission of both diseases.DPP^® HIV-SYPHILIS
requires minimal patient sample and provides actionable results in 20 minutes,
allowing for results and counseling at the point-of-care.Based on the market
need and the strength of these data, we intend to work with the regulatory
authorities to establish a pathway to approval for this much-needed
diagnostic."

In addition, the Company has two posters being presented at the Conference
today:

  *"Performance Evaluation of a Novel HIV-1/2 Rapid Test for the Detection of
    HIV-1/2 Antibodies in Oral Fluid and Whole Blood," which demonstrated the
    diagnostic sensitivity of the DPP^® HIV assay to detect HIV infection,
    currently pending FDA Pre-Marketing Application approval in point
    estimates ranging from 99.9% to 100% for fingerstick whole-blood specimens
    and 98.9% to 100% for oral-fluid specimens. The diagnostic specificity of
    the DPP^® HIV tests was 100% in all sites for fingerstick whole-blood
    specimens and 99.9% to 100% for oral-fluid specimens.The sensitivity
    estimate on oral-fluid specimens was lower in the United States (98.9%)
    compared with Mozambique and Nigeria (100%) mainly due to the known
    HIV-positive population. Approximately 84% (731/868) in the United States
    and 60% (129/215) in Nigeria of the known HIV-positive population
    recruited were taking antiretroviral drug therapy.
    
  *"Evaluation of the DPP® HIV-HCV-Syphilis Assay: a novel, point-of-care
    rapid HIV 1/2, HCV and Syphilis Treponema pallidum Antibody Combination
    Test," which indicated that DPP^® HIV-HCV-Syphilis assay, a rapid,
    qualitative multiplex POC test for the detection of antibodies to HIV 1/2,
    HCV and Syphilis Treponema pallidum in fingerstick whole blood, venous
    whole blood, serum or plasma, can be used to screen for HIV, HCV and
    Syphilis Treponema pallidum antibodies.Compared with the FDA-approved
    HIV, HCV and Syphilis Treponemal tests, all selected blood, sera and
    plasma samples tested with DPP HIV-HCV-Syphilis assay had 100% specificity
    for HIV and Syphilis Treponemal bands, and 100% and 99.4% specificity with
    blood and sera/plasma for HCV band, respectively.

"We are delighted to have this solid body of clinical data presented at the
2012 HIV Diagnostics Conference including the outstanding performance of our
HIV 1/2 test that is pending approval ," stated Lawrence Siebert, Chembio's
Chief Executive Officer."These data confirm the high sensitivity and
specificity of our DPP^® rapid assays in patients with HIV and HIV-related
infectious diseases.The simultaneous detection of multiple antibodies offers
the opportunity to increase diagnosis of and treatment for these highly
infectious diseases, which is hoped to reduce their transmission.As a result,
there continues to be a substantial interest in these products by public
health groups in the U.S. and abroad."

About the 2012 HIV Diagnostics Conference

The 2012 HIV Diagnostics Conference, co-sponsored by the Centers for Disease
Control and Prevention (CDC), the National Minority AIDS Council (NMAC), and
the Association of Public Health Laboratories (APHL), provides an opportunity
for clinicians, clinical and public health laboratorians, HIV/AIDS program
managers and directors, and industry representatives to review developments in
HIV diagnostics, share data and research findings, and establish
collaborations. Since its inception in 2005, the HIV Diagnostics Conference
has served as an opportunity for those interested in issues related to HIV
diagnostic testing to gather and discuss new developments and related
prevention and surveillance measures.

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets
proprietary rapid diagnostic tests in the growing $10 billion point-of-care
testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests
are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical
Innovations, Inc.). Chembio markets its HIV STAT-PAK^® line of rapid HIV tests
internationally to government and donor-funded programs directly and through
distributors. Chembio has developed a patented point-of-care test platform
technology, the Dual Path Platform (DPP^®) technology, which has significant
advantages over lateral-flow technologies.This technology is providing
Chembio with a significant pipeline of business opportunities for the
development and manufacture of new products based on DPP^®. Headquartered in
Medford, NY, with approximately 170 employees, Chembio is licensed by the U.S.
Food and Drug Administration (FDA) as well as the U. S. Department of
Agriculture (USDA), and is certified for the global market under the
International Standards Organization (ISO) directive 13.485.For additional
information, please visit the Company's website at www.chembio.com. 

Forward-Looking Statements

Statements contained herein that are not historical facts may be
forward-looking statements within the meaning of the Securities Act of 1933,
as amended.Forward-looking statements include statements regarding the
intent, belief or current expectations of the Company and its management.Such
statements, which are estimates only, reflect management's current views, are
based on certain assumptions, and involve risks and uncertainties.Actual
results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and will be
dependent upon a variety of factors, including, but not limited to Chembio's
ability to obtain additional financing and to obtain regulatory approvals in a
timely manner, as well as the demand for Chembio's products.Chembio
undertakes no obligation to publicly update these forward-looking statements
to reflect events or circumstances that occur after the date hereof or to
reflect any change in Chembio's expectations with regard to these
forward-looking statements or the occurrence of unanticipated events.Factors
that may impact Chembio's success are more fully disclosed in Chembio's most
recent public filings with the U.S. Securities and Exchange Commission.

CONTACT: Chembio Diagnostics
         Susan Norcott
         (631) 924-1135, ext. 125
         snorcott@chembio.com
        
         LHA
         Anne Marie Fields
         (212) 838-3777
         AFields@lhai.com
         @LHA_IR_PR